Home / Market News / $ENTX
benzinga Corporate Catalyst Impact 75/100 ● positive

Entera Bio Presents Phase 2 Data Supporting EB613 Benefits In Women With Osteoporosis At ASBMR 2026 Annual Meeting

Oct 13, 2026, 11:02 AM UTC · Primary ticker $ENTX

Entera Bio announced positive post-hoc Phase 2 data for its oral peptide EB613, showing greater bone mineral density gains in postmenopausal women with osteoporosis. This data supports the drug's potential benefit in a high-risk fracture population, aligning with the planned Phase 3 study and potentially de-risking future development.

Entera Bio presented post-hoc Phase 2 data for EB613, an oral peptide for osteoporosis, at the ASBMR 2026 Annual Meeting. The key finding was that EB613 demonstrated greater bone mineral density gains and an anabolic effect in women with osteoporosis (T-scores of ≤-2.5) compared to those with osteopenia. This is significant because it specifically highlights the drug's efficacy in the target population for its upcoming Phase 3 study, which focuses on postmenopausal women with osteoporosis at high risk for fracture. This positive data could de-risk the Phase 3 trial and provides a short-term positive catalyst for ENTX, potentially attracting investor interest and strengthening its long-term development prospects for EB613.

$ENTX positive Positive Phase 2 data for key drug candidate
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.